Research Biological Ageing Response to Recommendation
TOTAL SCORE: 10
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): +1
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): 0
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): 0
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): 0
D6 (Reorganisation): 0
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This recommendation scores high in Readiness (C) and Resourcefulness (D5: Resourcefulness).
The judicious use of biomarkers represents“ a move to market readiness” (C3). (D5: Resourcefulness), however is contingent on an accurate appraisal of existing assets. We recommend the formation of several leading AI Centres for Longevity, which will apply the latest advances in AI, Precision Health, Preventive Medicine and Biomarkers of Aging to accelerate the development of technologies, methods and services to increase the UK’s National Healthy Longevity.
The recommendation also scores high in Disruption (E) as research into biomarkers and hallmarks of aging is of critical importance not only to short term preventive solutions such as would be more than sufficient to meet the 2035 goal, but also to every facet of the emerging Longevity Industry as documented extensively by Aging Analytics Agency.
However, regarding D3: leveraging of cross-regional inputs: The role of artificial intelligence in biomarker development is frequently hinted at, e.g. in references to the use of AI in drug discovery, but never explicitly acknowledged. This recommendation only scores a +1 for D3 on the assumption that the critical role of AI in biomarker discovery is understood by the Committee.
RECOMMENDATION SUMMARY
“How to target ‘anti-ageing’ drugs to provide the greatest benefit to the individual, the NHS and society will be an important issue in future but requires further research and evidence from clinical trials. A health economics analysis of such treatments will be needed to determine the optimal time and populations for intervention. (Paragraph 170)
There has been a lack of effort since our report in 2005 to ensure research into ageing—as opposed to research into specific age-related disease—is properly funded, co-ordinated and included within the remit of particular research councils. This may have contributed to the poor translation of basic research into clinical trials or new medicines. (Paragraph 177)
We recommend that UK Research and Innovation commit to funding further research into the biological processes underlying ageing as a priority, in particular to address gaps in understanding the relevance of ageing hallmarks to humans. Research to identify accurate biomarkers of ageing in humans should also be prioritised, to support studies to improve health span. (Paragraph 178)”
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): +1
A3 (political viability): +1
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): +1
C1 (Market readiness applicability): 0
C2 (Project readiness): +1
C3 (Move to market readiness): +1
D1 (Actionability): 0
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): 0
D5 (Resourcefulness): 0
D6 (Reorganisation): 0
E (Disruptiveness): +2
F (Dividends - does the recommendation aid in social activity and inclusivity?): 0
This recommendation scores high in Readiness (C) and Resourcefulness (D5: Resourcefulness).
The judicious use of biomarkers represents“ a move to market readiness” (C3). (D5: Resourcefulness), however is contingent on an accurate appraisal of existing assets. We recommend the formation of several leading AI Centres for Longevity, which will apply the latest advances in AI, Precision Health, Preventive Medicine and Biomarkers of Aging to accelerate the development of technologies, methods and services to increase the UK’s National Healthy Longevity.
The recommendation also scores high in Disruption (E) as research into biomarkers and hallmarks of aging is of critical importance not only to short term preventive solutions such as would be more than sufficient to meet the 2035 goal, but also to every facet of the emerging Longevity Industry as documented extensively by Aging Analytics Agency.
However, regarding D3: leveraging of cross-regional inputs: The role of artificial intelligence in biomarker development is frequently hinted at, e.g. in references to the use of AI in drug discovery, but never explicitly acknowledged. This recommendation only scores a +1 for D3 on the assumption that the critical role of AI in biomarker discovery is understood by the Committee.
RECOMMENDATION SUMMARY
“How to target ‘anti-ageing’ drugs to provide the greatest benefit to the individual, the NHS and society will be an important issue in future but requires further research and evidence from clinical trials. A health economics analysis of such treatments will be needed to determine the optimal time and populations for intervention. (Paragraph 170)
There has been a lack of effort since our report in 2005 to ensure research into ageing—as opposed to research into specific age-related disease—is properly funded, co-ordinated and included within the remit of particular research councils. This may have contributed to the poor translation of basic research into clinical trials or new medicines. (Paragraph 177)
We recommend that UK Research and Innovation commit to funding further research into the biological processes underlying ageing as a priority, in particular to address gaps in understanding the relevance of ageing hallmarks to humans. Research to identify accurate biomarkers of ageing in humans should also be prioritised, to support studies to improve health span. (Paragraph 178)”